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To the Editor In a standard 1969 psychiatry textbook, Mayer-Gross and colleagues included patients with comorbid bipolar disorder (BD) and obsessive-compulsive disorders (OCD) in the manic-depressive disorders. Considering course of illness as a key diagnostic validator, the evidence so far on BD-OCD nosology supports the view that the majority of comorbid OCD cases appeared to be related to mood episodes (Tonna et al., 2015) . However, an optimal treatment approach remains to be defined.
We present the case of a patient with severe OCD who developed a manic episode during treatment with clomipramine.
The patient is a 24-year-old Caucasian woman with positive family history for recurrent depression. At 19 years of age, 2 weeks after delivery, she presented a major depressive episode that improved in the next few weeks with fluvoxamine 100 mg/day.
From the age of 22, she had gradually presented fear of contamination with hand washing more than 10 times per day, pathological doubts about daily events, and compulsive checking of light switches. These symptoms met Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, criteria for OCD. No history of manic episodes was reported.
She was admitted to the inpatient service and initially treated with fluvoxamine 200 mg/day without satisfactory control of obsessive-compulsive symptoms. Her therapy was modified to clomipramine 150 mg/day. After 4 weeks, she developed a manic episode. Her therapy was modified to lithium 900 mg/day and aripiprazole 30 mg/day. Aripiprazole was gradually decreased and lithium was continued with mood stabilization and remission of obsessive-compulsive symptoms.
After 3 months, washing and checking rituals increased prominently. Aripiprazole 10 mg/day was added to lithium and affective and obsessivecompulsive symptoms were well controlled for the following 12 months.
Positive family history for recurrent depression, postpartum onset of depressive episode, manic switch induced by antidepressant and improvement of affective and obsessive-compulsive symptoms with mood stabilizers and atypical antipsychotics, support the hypothesis of an underlying bipolarity (Tonna et al., 2015) .
Osler's view that medicine should be treatment of diseases, not of symptoms, is consistent with the approach of mood stabilization as the primary goal in treating apparent BD-OCD patients (Patra, 2016) , as opposed to immediate treatment with antidepressants that seemed to be less effective and more harmful in BD-OCD than in non-comorbid patients (Amerio et al., 2014) .
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The author(s) received no financial support for the research, authorship and/or publication of this article. To the Editor Lithium neurotoxicity usually occurs in the context of chronic therapeutic administration of lithium rather than an acute overdose of lithium, which highlights the need for vigilant monitoring in susceptible individuals (Oakley et al., 2001) . We describe a case of lithium toxicity and subsequent prolonged delirium to underscore the necessity for close monitoring and clinical assessment of individuals who are prescribed lithium. MR, a 63-year-old retiree with brittle bipolar disorder living in rural Australia, was hospitalized for over 3 months for treatment of depression. Historically, her bipolar illness was characterized by multiple affective switches followed by a lack of stability or return to euthymia. Upon admission, MR was found to be lithium toxic, and was immediately transferred to a general medical ward for treatment and stabilization. She was transferred back to our psychiatric unit on low-dose lithium. Her depressive episode was complicated by a protracted delirium, characterized by cognitive impairment, social withdrawal and reversal of her sleep-wake cycle. She resisted nonpharmacological interventions to manage her delirium and remained basically bed-bound, which contributed to other medical complications. Most of her psychotropic medications were reduced or ceased during this period, including lithium as she could no longer tolerate an increased dose without worsening confusion.
References
MR's lengthy delirium, which took 5 weeks to resolve, was likely a marker of her underlying brain vulnerability and decreased resilience to external triggers. The development of delirium is often multifactorial, especially in older individuals, with a complex interplay between predisposing and precipitating factors. Thus, prevention and treatment approaches must be multifaceted in nature. Prolonged delirium itself might lead to permanent cognitive decline, which is itself a predisposing factor for future episodes of delirium (Inouye et al., 2014) .
MR had right unilateral ultra-brief electroconvulsive therapy (ECT) to treat her severe depression, and her mood and psychomotor functioning gradually improved. However, she developed hypomania after her seventh treatment. ECT was suspended, and she was commenced on carbamazepine and quetiapine. Within approximately 1 week, her mood stabilized, and she was discharged in a euthymic state.
Lithium remains a highly effective treatment with Level 1 evidence for both unipolar and bipolar disorders, but its clinical use has to be tempered against potential side-effects and the need for ongoing monitoring (Malhi et al., 2016) . Individuals like MR who are living in remote areas may have limited access to psychiatric care, making proper monitoring even that much more difficult.
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